Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Status Recruiting

Clinical Trial Summary

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.

Clinical Trial Description

This is a phase II, open-label, non-randomized, multi-institutional study investigating postoperative or adjuvant human epidermal growth factor receptor (HER2)-directed therapy with adjuvant ado-trastuzumab emtansine (T-DM1) in HER2-positive salivary gland carcinomas (SGC). This research study is: - Studying the use of T-DM1 in combination with radiation and chemotherapy; and the use of maintenance T-DM1 alone for up to a year after surgery - Evaluating the effectiveness, safety, and toxicity of T-DM1 T-DM1 is a specialized antibody targeting HER-2 (a protein that is expressed in some breast and salivary gland cancers). The drug is a HER-2 antibody that is bound to a chemotherapy agent (DM1) and delivered intravenously. T-DM1 then binds cancer cells that express HER-2 and is taken up into the cell to allow DM1 to kill cancer cells in a more targeted way. This allows the use of a targeted treatment along with chemoradiation to treat HER-2 expressing salivary cancers. The U.S. Food and Drug Administration (FDA) has not approved T-DM1 for HER2-positive salivary gland cancer but it has been approved for other uses (for breast cancers that express HER2 protein). The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits. This research study involves radiation, chemotherapy, and targeted therapy given after surgery for up to 1-year, and participants will be followed for 3 years. It is expected that about 55 people will take part in this research study. Genentech is supporting this research study by providing the research study drug, T-DM1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04620187
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact	Glenn J Hanna, MD
Phone	617-632-3090
Email	glenn_hanna@dfci.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	December 24, 2020
Completion date	February 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03729297` - Cabozantinib in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT01969578` - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer	Phase 2
Completed	`NCT01703455` - Activity of Sorafenib in Salivary Gland Cancer	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Active, not recruiting	`NCT03781986` - APG-115 in Salivary Gland Cancer Trial	Phase 1/Phase 2
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05483374` - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT03172624` - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2
Completed	`NCT00509002` - Iressa Study in Patients With Salivary Gland Cancer	Phase 2
Active, not recruiting	`NCT05008237` - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study	Phase 2
Recruiting	`NCT03360890` - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors	Phase 2
Not yet recruiting	`NCT05898373` - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC	Phase 1/Phase 2
Active, not recruiting	`NCT02069730` - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	N/A
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Completed	`NCT01344356` - Stereotactic Body Radiotherapy for Head and Neck Tumors	Phase 4
Completed	`NCT03602079` - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.